Werkgroep Cardiologische centra Nederland

STRENGTH (Completed)

Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)
Medicine
epanova
Population
ASCVD
Phase
III
Starting year
2013
More information
ClinicalTrials.gov

Director of Study

dr. A.F.M. Kuijper (Cardioloog)
Haarlem, Spaarne Gasthuis

Publications: STRENGTH

  • Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trialsLancet - Martens, dr. F.M.A.C. [inactief]; Kuijper, dr. A.F.M. - STRENGTH - ASCVD
  • Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular RiskJAMA - Abstract - STRENGTH - ASCVD

Publications by WCN study

Publications WCN studies by WCN member